Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Avonex 15 Year Long Term Follow-up Study

Study:

Avonex® Fifteen Year Long Term Follow Up of Patients With Relapsing Multiple Sclerosis: ASSessment of Drug Utilization, EaRly TreAtmeNt, and Clinical OutcomEs

Rationale:

n/a

Purpose:

The Avonex Fifteen-year Long-term Follow-up of Patients with Relapsing Multiple Sclerosis: ASSessment of Drug Utilization, EaRly TreAtmeNt, and Clinical OutcomEs (ASSURANCE), was a single-time-point evaluation of patients conducted 15 years after the pivotal MSCRG study, evaluated the impact of IM IFNß-1a treatment on long-term disability and Quality of Life outcomes in patients who completed 2 years in a previous Multiple Sclerosis Collaborative Research Group (MSCRG) study.

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Multiple Sclerosis n/a Phase 4

Verified by Biogen Idec March, 2010

Sponsored by: Biogen Idec
Information provided by: Biogen Idec
ClinicalTrials.gov identifier: NCT00525343

Study Type: Interventional

Study Design: Observational Model: Cohort, Time Perspective: Retrospective

Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States

Pamela Foulds, MD., Study Director

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site